Found Subscription: How the Recurring Model Works

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Before enrolling in any recurring health program, it helps to understand exactly what a subscription commits you to. This independent review examines the Found subscription model. Browse the Peptides & GLP-1 education library.

This editorial analysis comes from PlexusDx. We hold no commercial relationship with Found or its parent company, and no affiliate links or compensation are involved.

Below we look at what subscribing actually means, how recurring billing and shipments are structured, what continuity of care looks like, and where the model has limits. Balanced framing, not a buying recommendation. As of April 2026.

What subscribing to Found means

A subscription is an ongoing relationship, not a one-time purchase. Enrolling typically commits a patient to recurring clinical access and medication fulfillment on a schedule, which is convenient but also worth reading carefully. The appeal is that reorders happen without repeated effort; the trade-off is that the commitment continues until you actively change it. The current terms for any program are set out on Found's own website, and they can change over time.

The recurring-billing model

Enrollment

A patient completes intake, and if a licensed clinician finds GLP-1 therapy appropriate, an ongoing plan begins.

Ongoing shipments

Medication is fulfilled on a recurring cadence through a retail or 503A compounding pharmacy, with follow-up along the way.

Cancellation considerations

Because billing recurs, the terms for pausing or ending a plan are worth confirming before enrolling.

Continuity of care in a subscription

One argument for the subscription structure is continuity: recurring follow-up supports dose titration and side-effect management over time rather than leaving a patient to manage adjustments alone. GLP-1 therapy is typically titrated in steps, so having a clinician reachable between shipments is a practical benefit rather than a marketing flourish. That continuity is a genuine feature of the model, distinct from the billing mechanics that make it recurring, and it is worth weighing separately from the convenience of automatic reorders.

What ships and how it is prescribed

What arrives depends on the compound and pathway. GLP-1 receptor agonists like semaglutide and the dual agonist tirzepatide are the usual options, sourced as branded (retail) or compounded (503A) preparations. Because the medication is prescription-only, every shipment still traces back to a clinician's decision rather than an automatic cart. The trial evidence, STEP (NEJM 2021) and SURMOUNT (NEJM 2022), describes those compounds rather than any subscription, and outcomes vary individually.

What a subscription cannot capture

A recurring plan schedules the medication but never reads the genetic baseline it acts on. Variants in MC4R, a melanocortin receptor central to satiety, and GLP1R, the receptor GLP-1 compounds target, describe that biology. These are pathway-level markers, not response predictions. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including MC4R and GLP1R variants that map your baseline satiety and receptor biology, context no shipping schedule provides.

The PlexusDx model and membership

PlexusDx pairs its Weight Management Protocols with that upstream genetic context, and program members pay $99 for the genetic test rather than $298. The model puts pathway insight alongside the protocol instead of shipping the protocol on its own, so the recurring relationship starts from an understanding of your baseline biology rather than from a reorder schedule alone.

No affiliation: PlexusDx is independent of Found and holds no commercial relationship with the programs discussed here.

More from the PlexusDx library: GLP 1 Hormone, What Is GLP 1, GLP 1 What Is, and GLP 1 Receptor Agonist.

Disclaimer: This article is educational. PlexusDx is not affiliated with Found and compares approaches across the GLP-1 telehealth space, including its own Weight Management Protocols. The Precision Peptide Genetic Test examines how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Frequently Asked Questions

What am I committing to with a Found subscription?

A subscription is an ongoing relationship with recurring clinical access and scheduled medication fulfillment rather than a single purchase. That structure is convenient but binds you to recurring billing, so read the enrollment and renewal terms carefully on the brand's own site before signing up.

How do recurring shipments work?

After enrollment and clinician approval, medication is fulfilled on a recurring cadence through a retail or 503A compounding pharmacy, with follow-up between shipments. The exact schedule and what arrives depend on the compound and pathway, so confirm the current cadence directly with the program.

Can I cancel a subscription easily?

Because billing recurs, cancellation and pause terms matter and vary by program. Confirm how to stop or adjust a plan before enrolling rather than after. Reviewing those terms upfront avoids surprises, since a subscription continues until you actively change or end it.

What does a subscription leave out?

A recurring plan schedules the medication but never reads your genetic baseline. Pathway-level variants such as MC4R and GLP1R describe the satiety and receptor biology a compound acts on. The Precision Peptide Genetic Test provides that upstream context, which no shipping schedule can capture.

Keep exploring the PlexusDx Education Hub. Browse Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.